Oxysterols regulate encephalitogenic CD4+ T cell trafficking during central nervous system autoimmunity

Journal of Autoimmunity

Volumn 56, Issue , 2015, Pages 45-55

  Chalmin, F ^a,b   Rochemont, V ^a,b   Lippens, C ^b   Clottu, A ^b   Sailer, A W ^c   Merkler, D ^a,d   Hugues, S ^b   Pot, C ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Autoimmunity; CD4+ T lymphocytes; Cholesterol 25 hydroxylase (Ch25h); Experimental autoimmune encephalomyelitis; Oxysterols; Trafficking

Indexed keywords

7ALPHA,25 DIHYDROXYCHOLESTEROL; BIOLOGICAL MARKER; CHOLESTEROL; CHOLESTEROL 25 HYDROXYLASE; EPSTEIN BARR VIRUS INDUCED GENE 2; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 17; OXYGENASE; OXYSTEROL; PROTEIN; UNCLASSIFIED DRUG; ANTIGEN; CHOLESTEROL 25-HYDROXYLASE; CHOLESTEROL DERIVATIVE; CYTOKINE; GPR183 PROTEIN, MOUSE; STEROID MONOOXYGENASE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENE DELETION; HUMAN; HUMAN CELL; LEUKOCYTE; MOLECULAR MECHANICS; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; T LYMPHOCYTE SUBPOPULATION; ANIMAL; B LYMPHOCYTE; BIOSYNTHESIS; CELL MOTION; CYTOLOGY; DEFICIENCY; DENDRITIC CELL; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPH NODE; LYMPHOCYTE ACTIVATION; METABOLISM; MONOCYTE; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS; ANTIGENS, CD44; AUTOIMMUNITY; B-LYMPHOCYTE SUBSETS; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; HYDROXYCHOLESTEROLS; INTERLEUKIN-17; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; MONOCYTES; RECEPTORS, G-PROTEIN-COUPLED; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; STEROID HYDROXYLASES;

EID: 84920284167     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.10.001     Document Type: Article

References (36)

1. Weinstock-Guttman B., Zivadinov R., Horakova D., Havrdova E., Qu J., Shyh G., et al. Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event. JNeurol Neurosurg Psychiatry 2013, 84:1186-1191.
2. Marrie R.A., Rudick R., Horwitz R., Cutter G., Tyry T., Campagnolo D., et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010, 74:1041-1047.
3. Weinstock-Guttman B., Zivadinov R., Mahfooz N., Carl E., Drake A., Schneider J., et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. JNeuroinflammation 2011, 8:127.
4. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
5. Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., Markovic-Plese S., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004, 363:1607-1608.
6. Sorensen P.S., Lycke J., Eralinna J.P., Edland A., Wu X., Frederiksen J.L., et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol 2011, 10:691-701.
7. Chataway J., Schuerer N., Alsanousi A., Chan D., MacManus D., Hunter K., et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014, 383:2213-2221.
8. Spann N.J., Glass C.K. Sterols and oxysterols in immune cell function. Nat Immunol 2013, 14:893-900.
9. Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003, 72:137-174.
10. Leoni V., Masterman T., Diczfalusy U., De Luca G., Hillert J., Bjorkhem I. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett 2002, 331:163-166.
11. Pikuleva I.A. Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos Biol Fate Chem 2006, 34:513-520.
12. Bauman D.R., Bitmansour A.D., McDonald J.G., Thompson B.M., Liang G., Russell D.W. 25-Hydroxycholesterol secreted by macrophages in response to toll-like receptor activation suppresses immunoglobulin A production. Proc Natl Acad Sci U S A 2009, 106:16764-16769.
13. Yi T., Wang X., Kelly L.M., An J., Xu Y., Sailer A.W., et al. Oxysterol gradient generation by lymphoid stromal cells guides activated B cell movement during humoral responses. Immunity 2012, 37:535-548.
14. Blanc M., Hsieh W.Y., Robertson K.A., Kropp K.A., Forster T., Shui G., et al. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Immunity 2013, 38:106-118.
15. Liu S.Y., Aliyari R., Chikere K., Li G., Marsden M.D., Smith J.K., et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 2013, 38:92-105.
16. Hannedouche S., Zhang J., Yi T., Shen W., Nguyen D., Pereira J.P., et al. Oxysterols direct immune cell migration via EBI2. Nature 2011, 475:524-527.
17. Gatto D., Wood K., Caminschi I., Murphy-Durland D., Schofield P., Christ D., et al. The chemotactic receptor EBI2 regulates the homeostasis, localization and immunological function of splenic dendritic cells. Nat Immunol 2013, 14:446-453.
18. Yi T., Cyster J.G. EBI2-mediated bridging channel positioning supports splenic dendritic cell homeostasis and particulate antigen capture. eLife 2013, 2:e00757.
19. Ko H.J., Brady J.L., Ryg-Cornejo V., Hansen D.S., Vremec D., Shortman K., et al. GM-CSF-responsive monocyte-derived dendritic cells are pivotal in Th17 pathogenesis. JImmunol 2014, 192:2202-2209.
20. Sobel R.A., Greer J.M., Kuchroo V.K. Minireview: autoimmune responses to myelin proteolipid protein. Neurochem Res 1994, 19:915-921.
21. Papassotiropoulos A., Lambert J.C., Wavrant-De Vrieze F., Wollmer M.A., von der Kammer H., Streffer J.R., et al. Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease. Neuro-degenerative Dis 2005, 2:233-241.
22. Laumet G., Chouraki V., Grenier-Boley B., Legry V., Heath S., Zelenika D., et al. Systematic analysis of candidate genes for Alzheimer's disease in a French, genome-wide association study. Journal of Alzheimer's disease. JAD 2010, 20:1181-1188.
23. Rao M.L., Lutjohann D., Ludwig M., Kolsch H. Induction of apoptosis and necrosis in human neuroblastoma cells by cholesterol oxides. Ann N. Y Acad Sci 1999, 893:379-381.
24. Liu C., Yang X.V., Wu J., Kuei C., Mani N.S., Zhang L., et al. Oxysterols direct B-cell migration through EBI2. Nature 2011, 475:519-523.
25. Preuss I., Ludwig M.G., Baumgarten B., Bassilana F., Gessier F., Seuwen K., et al. Transcriptional regulation and functional characterization of the oxysterol/EBI2 system in primary human macrophages. Biochem Biophys Res Commun 2014, 446(3):663-668.
26. Park K., Scott A.L. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. JLeukoc Biol 2010, 88:1081-1087.
27. Reboldi A., Dang E.V., McDonald J.G., Liang G., Russell D.W., Cyster J.G. Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. Science 2014, 345:679-684.
28. Bjorkhem I., Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004, 24:806-815.
29. Gosselet F., Saint-Pol J., Fenart L. Effects of oxysterols on the blood-brain barrier: implications for Alzheimer's disease. Biochem Biophys Res Commun 2014, 446(3):687-691.
30. Gold E.S., Diercks A.H., Podolsky I., Podyminogin R.L., Askovich P.S., Treuting P.M., et al. 25-Hydroxycholesterol acts as an amplifier of inflammatory signaling. Proc Natl Acad Sci U S A 2014, 111:10666-10671.
31. Gold E.S., Ramsey S.A., Sartain M.J., Selinummi J., Podolsky I., Rodriguez D.J., et al. ATF3 protects against atherosclerosis by suppressing 25-hydroxycholesterol-induced lipid body formation. JExp Med 2012, 209:807-817.
32. Brocke S., Piercy C., Steinman L., Weissman I.L., Veromaa T. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A 1999, 96:6896-6901.
33. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
34. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. JImmunol 2006, 177:566-573.
35. Korn T., Reddy J., Gao W., Bettelli E., Awasthi A., Petersen T.R., et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007, 13:423-431.
36. Rothhammer V., Heink S., Petermann F., Srivastava R., Claussen M.C., Hemmer B., et al. Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE. JExp Med 2011, 208:2465-2476.